Alector (ALEC) Set to Announce Quarterly Earnings on Wednesday

Alector (NASDAQ:ALEC) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Alector (NASDAQ:ALEC) last released its earnings results on Wednesday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.10. Alector had a negative return on equity of 71.80% and a negative net margin of 125.11%. The company had revenue of $15.89 million for the quarter, compared to analysts’ expectations of $14.63 million. On average, analysts expect Alector to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alector Price Performance

NASDAQ ALEC traded up $0.07 on Tuesday, hitting $5.13. 189,128 shares of the company’s stock were exchanged, compared to its average volume of 662,971. Alector has a fifty-two week low of $3.66 and a fifty-two week high of $8.90. The firm’s 50-day moving average price is $5.08 and its two-hundred day moving average price is $5.62. The firm has a market cap of $494.46 million, a price-to-earnings ratio of -3.70 and a beta of 0.72.

Insider Activity at Alector

In related news, CEO Arnon Rosenthal sold 25,135 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $4.80, for a total value of $120,648.00. Following the completion of the sale, the chief executive officer now directly owns 1,975,245 shares in the company, valued at approximately $9,481,176. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Alector news, CFO Marc Grasso sold 6,920 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $4.80, for a total value of $33,216.00. Following the completion of the transaction, the chief financial officer now directly owns 138,037 shares of the company’s stock, valued at approximately $662,577.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Arnon Rosenthal sold 25,135 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $4.80, for a total transaction of $120,648.00. Following the completion of the transaction, the chief executive officer now directly owns 1,975,245 shares of the company’s stock, valued at $9,481,176. The disclosure for this sale can be found here. In the last three months, insiders sold 40,095 shares of company stock worth $192,456. Corporate insiders own 9.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ALEC shares. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Alector in a research note on Thursday, June 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Alector in a research note on Monday, July 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $14.00.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.